Utilisation of systemic therapy options in routine treatment of metastatic colorectal cancer in Australia
Internal Medicine Journal2019Vol. 50(2), pp. 165–172
Citations Over Time
Rachel Delahunty, Margaret Lee, Hui‐Li Wong, Julie Johns, Joseph McKendrick, Belinda Lee, Suzanne Kosmider, Prasad Cooray, Sumitra Ananda, Jayesh Desai, Ben Tran, Jeanne Tie, Peter Gibbs, Rachel Wong
Abstract
In this community-based cohort, 33% of patients had not received any systemic therapy for mCRC, and few patients had received all available active systemic agents. As many patients remain alive, these figures will likely increase over time. The overall survival of patients with mCRC in this community-based cohort was 25 months and not dissimilar to that achieved in recent clinical trials.
Related Papers
- → Targeting colorectal cancer with human anti-EGFR monoclonocal antibodies: focus on panitumumab(2008)47 cited
- → Treatment with Panitumumab After a Severe Infusion Reaction to Cetuximab in a Patient with Metastatic Colorectal Cancer: A Case Report(2007)45 cited
- → The effectiveness of cetuximab and panitumumab when combined with FOLFIRI in second-line treatment of KRAS wild type metastatic colorectal cancers. Single centre experience(2020)2 cited
- → The Cost Study of Cetuximab and Panitumumab in The First-Line Treatment of Mcrc in The Czech Republic(2017)
- ASPECCT: panitumumab versus cetuximab for colorectal cancer(2014)